Additionally, LY2510924, another potent CXCR4 peptide antagonist, led to a phase 1 study that demonstrated safety and yielded a response signal in patients with relapsed/refractory AML in combination with Idarubicin, and cytarabine [121]. Here, CXCR4 is linked to acute myeloid leukemia.